Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director · Chief Executive Officer | May 29, 2019 | May 31, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date May 29, 2019 · Filed May 31, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 290,687 |
Last balance in matching sequence
After 2019-05-30 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2019-05-29 · Sale · Disposed 2,200 · Balance 294,337 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.21 to $23.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 2 · 2019-05-29 · Sale · Disposed 725 · Balance 293,612 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.23 to $23.335. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 3 · 2019-05-30 · Sale · Disposed 1,425 · Balance 292,187 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.48 to $23.365. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 4 · 2019-05-30 · Sale · Disposed 1,500 · Balance 290,687 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.54 to $23.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. |
| Common StockSEC Table I · non-derivative | Direct | 332,243 |
Reported balance
Holding disclosure · report date 2019-05-29 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 332,243 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018.
F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.21 to $23.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
F4: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.23 to $23.335. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.48 to $23.365. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.54 to $23.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2017 Filed May 31, 2017 19:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,450 | $13.26 | $45,747.00 |
DisclosureSEC source: 0001209191-17-036609 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 456,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.00 to $13.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 30, 2017 Filed May 31, 2017 19:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,450 | $13.44 | $46,368.00 |
DisclosureSEC source: 0001209191-17-036609 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 459,528 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.10 to $14.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 18, 2017 Filed May 19, 2017 16:05 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $14.94 | $35,856.00 |
DisclosureSEC source: 0001209191-17-033914 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 462,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.70 to $15.075. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 17, 2017 Filed May 19, 2017 16:05 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $14.88 | $35,712.00 |
DisclosureSEC source: 0001209191-17-033914 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 465,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.65 to $15.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:59 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 5,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033198 · doc4.xml · derivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,754 Underlying: Common Stock · 5,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:59 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 5,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033198 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| April 26, 2017 Filed Apr 26, 2017 19:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,600 | $17.78 | $64,008.00 |
DisclosureSEC source: 0001209191-17-028273 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 467,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.50 to $17.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 19:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,500 | $17.70 | $26,550.00 |
DisclosureSEC source: 0001209191-17-028273 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 471,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.55 to $17.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 19:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,100 | $17.07 | $35,847.00 |
DisclosureSEC source: 0001209191-17-028273 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 472,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.55 to $17.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 11, 2017 Filed Apr 12, 2017 16:20 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,200 | $16.99 | $71,358.00 |
DisclosureSEC source: 0001209191-17-026678 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 474,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.75 to $17.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 16:20 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,000 | $17.08 | $51,240.00 |
DisclosureSEC source: 0001209191-17-026678 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 479,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.70 to $17.60. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 28, 2017 Filed Mar 28, 2017 20:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 418 | $19.86 | $8,301.48 |
DisclosureSEC source: 0001209191-17-023215 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 482,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.65 to $20.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 28, 2017 Filed Mar 28, 2017 20:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,182 | $18.99 | $60,426.18 |
DisclosureSEC source: 0001209191-17-023215 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 482,596 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.55 to $19.525. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 27, 2017 Filed Mar 28, 2017 20:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 12,400 | $20.34 | $252,216.00 |
DisclosureSEC source: 0001209191-17-023215 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 485,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 18:50 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 17,600 | $20.01 | $352,176.00 |
DisclosureSEC source: 0001209191-17-021840 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 498,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.20 to $20.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 18:50 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $18.50 | $44,400.00 |
DisclosureSEC source: 0001209191-17-021840 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 515,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.20 to $19.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 18:50 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 10,800 | $18.54 | $200,232.00 |
DisclosureSEC source: 0001209191-17-021840 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 518,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.25 to $19.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 20:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $15.57 | $37,368.00 |
DisclosureSEC source: 0001209191-17-011763 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 348,978 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.35 to $16.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 5,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011763 · doc4.xml · derivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,662 Underlying: Common Stock · 5,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F8 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F9 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $15.54 | $37,296.00 |
DisclosureSEC source: 0001209191-17-011763 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 351,378 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.35 to $16.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 5,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011763 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 17:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 165,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008814 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,044 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 17:29 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $13.87 | $33,288.00 |
DisclosureSEC source: 0001209191-17-008079 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 353,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.35 to $14.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 17:29 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $13.45 | $32,280.00 |
DisclosureSEC source: 0001209191-17-008079 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 356,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.35 to $13.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 18, 2017 Filed Jan 19, 2017 16:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $14.47 | $34,728.00 |
DisclosureSEC source: 0001209191-17-004502 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 358,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.25 to $14.60. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 16:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,600 | $14.08 | $50,688.00 |
DisclosureSEC source: 0001209191-17-004502 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 360,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.975 to $14.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 06, 2017 Filed Jan 9, 2017 16:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,000 | $17.10 | $102,600.00 |
DisclosureSEC source: 0001209191-17-002930 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 364,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.80 to $17.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 16:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $16.36 | $39,264.00 |
DisclosureSEC source: 0001209191-17-002930 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 370,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.10 to $16.675. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 23, 2016 Filed Dec 23, 2016 18:52 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $15.25 | $36,600.00 |
DisclosureSEC source: 0001209191-16-156701 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 372,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.10 to $15.625. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 22, 2016 Filed Dec 23, 2016 18:52 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 100 | $15.82 | $1,582.00 |
DisclosureSEC source: 0001209191-16-156701 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 375,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.80 to $15.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 22, 2016 Filed Dec 23, 2016 18:52 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,300 | $15.17 | $34,891.00 |
DisclosureSEC source: 0001209191-16-156701 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 375,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.55 to $15.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 17:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,600 | $17.30 | $62,280.00 |
DisclosureSEC source: 0001209191-16-154212 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 377,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.05 to $17.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 17:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,600 | $18.55 | $66,780.00 |
DisclosureSEC source: 0001209191-16-154212 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 381,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.25 to $18.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 23, 2016 Filed Nov 23, 2016 20:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,100 | $19.22 | $21,142.00 |
DisclosureSEC source: 0001209191-16-152005 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 384,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.00 to $19.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 23, 2016 Filed Nov 23, 2016 20:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,500 | $18.40 | $46,000.00 |
DisclosureSEC source: 0001209191-16-152005 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 386,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.95 to $18.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 20:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 8,400 | $18.21 | $152,964.00 |
DisclosureSEC source: 0001209191-16-152005 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 388,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.85 to $18.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 16:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 5,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150918 · doc4.xml · derivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,569 Underlying: Common Stock · 5,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 16:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 5,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150918 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| October 27, 2016 Filed Oct 28, 2016 20:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $13.70 | $32,880.00 |
DisclosureSEC source: 0001209191-16-147360 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 396,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.40 $14.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 26, 2016 Filed Oct 28, 2016 20:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $13.91 | $33,384.00 |
DisclosureSEC source: 0001209191-16-147360 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 399,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.80 to $14.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 14, 2016 Filed Oct 17, 2016 16:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $16.01 | $38,424.00 |
DisclosureSEC source: 0001209191-16-146047 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 401,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.725 to $16.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 13, 2016 Filed Oct 17, 2016 16:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,400 | $15.91 | $38,184.00 |
DisclosureSEC source: 0001209191-16-146047 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 404,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.70 to $16.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 28, 2016 Filed Sep 29, 2016 16:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 300 | $21.82 | $6,546.00 |
DisclosureSEC source: 0001209191-16-143144 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. Read SEC document |
| September 28, 2016 Filed Sep 29, 2016 16:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,500 | $21.40 | $96,300.00 |
DisclosureSEC source: 0001209191-16-143144 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 406,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.81 to $21.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 27, 2016 Filed Sep 29, 2016 16:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,200 | $20.50 | $147,600.00 |
DisclosureSEC source: 0001209191-16-143144 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 411,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.03 to $20.84. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 22, 2016 Filed Sep 23, 2016 19:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 320,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142706 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,136 F1 · shares: These restricted stock units vest over 4 years, 50% on the 2nd anniversary of the grant date of September 22, 2016 and 25% on the anniversary of the grant date of September 22, 2016 in each of the following years. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 17:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,600 | $19.32 | $69,552.00 |
DisclosureSEC source: 0001209191-16-142020 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 418,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.00 to $19.94. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 17:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,600 | $19.39 | $69,804.00 |
DisclosureSEC source: 0001209191-16-142020 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 422,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.03 to $19.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.